162 related articles for article (PubMed ID: 35702037)
41. Limb melanomas: acral melanomas have worse survival.
Tas F; Erturk K
J Dermatolog Treat; 2022 May; 33(3):1630-1637. PubMed ID: 33470132
[TBL] [Abstract][Full Text] [Related]
42. Acral lentiginous melanoma: Clinicopathologic and survival differences according to tumour location.
Howard M; Xie C; Wee E; Wolfe R; McLean C; Kelly JW; Pan Y
Australas J Dermatol; 2020 Nov; 61(4):312-317. PubMed ID: 32363586
[TBL] [Abstract][Full Text] [Related]
43. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma.
Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q
Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy.
Gajón JA; Juarez-Flores A; De León Rodríguez SG; Aguilar Flores C; Mantilla A; Fuentes-Pananá EM; Bonifaz LC
Arch Med Res; 2022 Dec; 53(8):794-806. PubMed ID: 36460547
[TBL] [Abstract][Full Text] [Related]
46. Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
Haugh AM; Zhang B; Quan VL; Garfield EM; Bubley JA; Kudalkar E; Verzi AE; Walton K; VandenBoom T; Merkel EA; Lee CY; Tan T; Isales MC; Kong BY; Wenzel AT; Bunick CG; Choi J; Sosman J; Gerami P
J Invest Dermatol; 2018 Feb; 138(2):384-393. PubMed ID: 28870692
[TBL] [Abstract][Full Text] [Related]
47. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
48. Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2016 Jan; 53():125-34. PubMed ID: 26707829
[TBL] [Abstract][Full Text] [Related]
49. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
50. Targeted molecular therapy in melanoma.
Puzanov I; Flaherty KT
Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
[TBL] [Abstract][Full Text] [Related]
51. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
52. Histopathological diagnosis of acral lentiginous melanoma in early stages.
Fernandez-Flores A; Cassarino DS
Ann Diagn Pathol; 2017 Feb; 26():64-69. PubMed ID: 27601330
[TBL] [Abstract][Full Text] [Related]
53. The safety of nivolumab for the treatment of metastatic melanoma.
O'Reilly A; Larkin J
Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
[TBL] [Abstract][Full Text] [Related]
54. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
55. Melanomas of the palm, sole, and nailbed: a clinicopathologic study.
Feibleman CE; Stoll H; Maize JC
Cancer; 1980 Dec; 46(11):2492-504. PubMed ID: 7438021
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
57. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
58. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
[TBL] [Abstract][Full Text] [Related]
59. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
60. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
